Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 7, 2009

Nexus Biosystems Nabs Aurora Biotechnologies

  • Nexus Biosystems acquired Aurora Biotechnologies, thus expanding into high-throughput biochemical, cell-based, and genomic screening applications. The company has traditionally provided technologies and automated sample-management systems to pharmaceutical, biotech, agrichemical, and research institutions.

    Aurora serves the discovery research markets with consumable microplate products that enable high-throughput analysis of chemical compounds and cellular assays. Its offerings include a range of high-performance microplate designs including 1,536- and 3,456-well plates.   

    “Aurora’s legacy in understanding key processes in assay technologies and consumables is a great fit with the Nexus sample-management and sample-processing technologies,” Peter Coassin, president and chief technical officer of Aurora.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »